ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 549

Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort

E Alemao1, LR Harrold2, HJ Litman3, SE Connolly4, S Kelly1, W Hua3, L Rosenblatt1, S Rebello5 and JM Kremer6, 1Bristol-Myers Squibb, Princeton, NJ, 2University of Massachusetts Medical School, Worcester, MA, 3Corrona, Southborough, MA, 4Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, 5Epidemiology, Corrona, Southborough, MA, 6The Albany Medical College, Albany, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy and prognostic factors, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A number of studies have demonstrated the association between disease activity and work productivity in patients (pts) with RA. However, the relationship between work status and poor prognosis is unknown. This analysis characterized the proportion of pts with RA who had poor prognoses in an observational clinical cohort and evaluated poor prognostic factors and pts’ work status.

Methods: Using the Corrona RA registry, we identified pts with RA who were biologic naïve at enrollment and had a follow-up visit at 12 months (± 3 months). Pts were characterized by RA prognosis based on factors from the 2008 ACR treatment recommendations,1 including functional limitation (modified Health Assessment Questionnaire), extra-articular disease (Sjögren’s syndrome, RA lung disease and/or nodules), seropositivity (RF and/or anti-cyclic citrullinated peptide antibodies) and erosions. Pts were categorized as having 0–1, 2 or 3+ poor prognostic indicators. Pts with missing information on any factor were excluded. Each of the three prognosis groups was compared at enrollment (including use of prior conventional synthetic DMARDs) according to use of TNF inhibitors vs non-TNF inhibitors. The relationship between poor prognosis category and work status was investigated at baseline and 12 months using a chi-squared test. A dichotomous variable was constructed, with working ‘yes’ defined as full- or part-time working, and working ‘no’ including pts who worked from home or were students, disabled or retired. Because a relationship between poor prognosis and work status might be driven by age differences (retirees are generally older), a frequency-matching approach was used to match people across poor prognosis categories according to age group (18–44, 45–54, 55-64, 65–74, 75+ years).

Results: 3621 pts who enrolled in Corrona on/after January 2005 met the selection criteria: 1554 (42.9%), 1263 (34.9%) and 804 (22.2%) with a prognosis category of 0–1, 2 or 3+, respectively. Pts in the worst prognostic category were older (median age: 62 vs 58 years), had more established disease (median disease duration: 4 vs 1 years) and greater disease activity (median CDAI score: 14 vs 7) compared with those in the best prognosis category. After adjusting for age, there was a significant relationship between work and poor prognosis category; pts in the worst prognosis category were less likely to be in full- or part-time work at enrollment compared with those in the best prognosis category (p<0.001; Table). At the 12-month visit, the relationship between poor prognosis category and work status remained statistically significant (p<0.001; Table).

Conclusion: These data suggest that the proportion of pts with RA in full- or part-time employment was lower in those with poor prognostic factors. Further studies are needed to investigate whether treatment can prevent or reverse impairment of work status in pts with RA. 1. Saag K, et al. Arthritis Rheum 2008;59:762–84.    

Table. Work status (full time/part time) at enrollment and at the 12-month visit by poor prognosis category after adjusting for age
  Poor prognosis indicators  
  0–1 2 3+ p value*
Work status at enrollment
Full time/part time, n (%) 398 (49.5) 351 (43.7) 297 (37.0) <0.001
All others,† n 406 (50.5) 453 (56.3) 506 (63.0)
Total, n 804 804 803
Work status at 12-month visit
Full time/part time, n (%) 383 (48.9) 314 (39.6) 277 (35.3) <0.001
All others,† n 401 (51.1) 479 (60.4) 508 (64.7)
Total, n 784 793 785
*p value is calculated based on a chi-squared test of any relationship between work status and poor prognosis category; †worked from home or who were students, disabled or retired.
 

Disclosure: E. Alemao, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; L. Harrold, Corrona, LLC, 1,Pfizer Inc, 2; H. Litman, Corrona, LLC, 3; S. Connolly, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; S. Kelly, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; W. Hua, Corrona, LLC, 3; L. Rosenblatt, Bristol-Myers Squibb, 1,Bristol-Myers Squibb, 3; S. Rebello, Corrona, LLC, 3; J. Kremer, Corrona, LLC, 1,AbbVie, Bristol-Myers Squibb, Genentech, Lilly, Novartis, Pfizer, 2,Corrona, LLC, 3,Genentech, 8.

To cite this abstract in AMA style:

Alemao E, Harrold L, Litman H, Connolly S, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer J. Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/work-status-in-patients-with-rheumatoid-arthritis-who-have-poor-prognostic-factors-findings-from-a-us-observational-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/work-status-in-patients-with-rheumatoid-arthritis-who-have-poor-prognostic-factors-findings-from-a-us-observational-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology